Noscendo – tHe company
Noscendo GmbH is the leading global provider of software-based pathogen identification technology. We’ve made it our objective to revolutionise infection diagnostics, thus saving patient lives.
Scores of well-known university hospitals, major regional hospitals and hospital groups are already using DISQVER. We also work with several health insurance providers.
We have already received a host of awards for our pioneering approach. Noscendo was named Health-i Pioneer 2020 by Handelsblatt and Techniker Krankenkasse (TK). The award honours highly innovative ideas in the healthcare sector. In 2019, the scientific project behind DISQVER was awarded the ‘SIK Innovation Prize 2019’ by the Stuttgart Intensive Care Congress (SIK).
Noscendo in numbers
Approval of DISQVER analysis platform
Sites, Tübingen and Duisburg
Next-Generation Sequencing-Based Decision Support for Intensivists in Difficult-to-Diagnose Disease States
Software driven NGS-based diagnostics company Noscendo secures funding to revolutionize the diagnosis of infectious diseases
Series B led by a renowned family office focused on life sciences, with impact-focused VC Revent as co-investor, plus support from existing investorsFurther development of proprietary DISQVER® technology and international expansion Duisburg, May 16, 2022 –...
Noscendo GmbH, a leading diagnostic company for identification and assessment of bloodstream associated pathogens and other infections announced today the addition of Heiner Dreismann, former President and CEO of Roche Molecular Systems, to its Board of Directors
Dr. Jennifer Axnick
Technical Key Account Manager
Dr. Marcus Benz
Chief Operating Officer
Vice President Bio & Information Technology
Dr. Frauke Diekmann
Key Account Manager
Dr. Claudia Disque
Dr. Silke Grumaz
Chief Scientific Officer, Co-Founder
Dr. Peter Haug
Chief Strategy Officer, Co-Founder
Senior Software Developer
Customer Success Agent
DR. BETTINA HOFER
Medical Project Management
Dr. Rafael Holzem
Quality Management Representative
Dr. Petra Horvatek
Customer Success Agent
Key Account Manager
Teamlead Clinical Trials
Dr. Sonia Mazitelli
Head of Sales
Vice President Digital Integration
Dr. Philip Stevens
Chief Executive Officer, Co-Founder
Dr. Sandra Unsleber
Scientist for NGS-based diagnostics
Chief Commercial Officer
Strategic And Scientific Advisory Board
Prof. Dr. Arndt von Haeseler
Prof. von Haeseler is Head of CIBIV (Center for Integrative Bioinformatics Vienna) at the Max Perutz Labs, where he also served as the scientific director. In 2015, von Haeseler was elected as a corresponding member in Austria of the mathematics and science class of the Austrian Academy of Sciences.
Dr. Trevor Hawkins
Dr Hawkins’ 25+ year career in healthcare has included business, academic innovation and entrepreneurship. Dr Hawkins was previously Director of the Human Genome Project for the US DOE, and has held senior executive roles at Siemens Healthcare, Philips, GE Healthcare and Amersham.
Dr. Michael Lutz
Dr Lutz is an experienced biotech entrepreneur who has spent the last 15 years leading several life sciences companies until their successful exit. Before he was appointed CEO/Managing Director of HepaRegeniX in 2019, he built and led LifeCodexx as the leading cfDNA-based NIPT provider from inception to reimbursement in several European countries. Dr Lutz holds a PhD in Bioorganic Chemistry from ETH Zurich (Switzerland).
Prof. Dr. James Rothman
Prof. Rothman is a highly distinguished biochemist and Sterling Professor of Cell Biology at Yale University who was awarded the 2013 Nobel Prize in Physiology/Medicine. Prof. Rothman serves, among other positions, as Chair of the Yale School of Medicine’s Department of Cell Biology and is the Director and founder of the Nanobiology Institute on Yale’s new West Campus.
Prof. Dr. Felix Wieland
Prof. Wieland is an elected Member of the Academia Europea and the National Academy of Sciences, Leopoldina, as well as an honorary member of the Charité (Medical Faculty of Humboldt University Berlin) and is a Senior Professor for Biochemistry at Heidelberg University. Prof. Wieland’s main areas of research are Enzymology, Glycobiology and Molecular Membrane Biology, including the specificity of lipid-protein interactions.